CAR-T cell therapy - China Intellectual Property Lawyers Network

+86-13910160652

EN

CHINA intellectual PROPERTY LAWYERS NETWORK

Chief Lawyer Xu Xinming

Chief Lawyer Xu Xinming

+86-13910160652 ciplawyers@163.com

About Us Consultation

Working Progress

more >

Xu Xinming: Can the Trademark Right of Zhengongfu Beat Bruce Lee’s Portrait Right?
Lasted for Eight Years: Won the Case Concerning the Administrative Dispute over Invalidation of the Invention Patent of Elecon Handled by Lawyer Xu Xinming
IMECAS v. Intel Series Cases of Patent Infringement Disputes
Winning the Case Concerning Dispute over Copyright Transfer Contract of the Musical “Race for Love” Represented by Lawyer Xu Xinming
The Wall Street Journal-Interview-Chief Lawyer Xu Xinming: Delivery Giant Meituan Fined in Beijing’s Tech Crackdown

IP Express

more >

Judicial Development

more >

CASE

more >

IP Theory

more >

IP Practice&View

more >

Determination of "Malice" in Malicious Patent Litigation

Determination of "Malice" in Malicious Patent Litigation

legal System

more >

Chinese Law Library

International Law Library

CAR-T cell therapy

BMS and Johnson & Johnson battle over novel CAR-T cell therapy in Europe

Office. Bristol Myers Squibb and Johnson & Johnson are competitors in the market for novel cancer therapies known to experts as CAR-T cell therapies. In 2025, BMS acquired the US cell and gene therapy

Post Time：2026.02.24

1

total 1 pages, 1 items

+86-13910160652